Anika Therapeutics, INC Form 4 insider transactions

Director Stephen Richard reports acquiring and disposing of Anika Therapeutics common stock and restricted stock units.

Director Glenn R. Larsen reports acquisition of 5,771 restricted stock units in Anika Therapeutics, Inc.

Director William Jellison reports acquisition of restricted stock units and transfer of common stock to a revocable trust.

Director John B. Henneman III of Anika Therapeutics reports acquisition and disposal of common stock and restricted stock units.

Director Gary P. Fischetti of Anika Therapeutics reports acquisition and disposal of common stock and restricted stock units.

Director Sheryl L. Conley reported the acquisition of restricted stock units in Anika Therapeutics, Inc.

Director Joseph H. Capper reports acquisition and disposal of Anika Therapeutics stock on July 9, 2024, according to a Form 4 filing.

Director William R. Jellison acquired 468 restricted stock units (RSUs) of Anika Therapeutics, Inc. on June 3, 2024.

Stephen D. Griffin, EVP, CFO and Treasurer of Anika Therapeutics, reports the acquisition of stock options and restricted stock units.

Director Joseph H. Capper acquired 468 restricted stock units (RSUs) of Anika Therapeutics, Inc. on June 3, 2024, which will vest on the earlier of the next annual meeting or June 3, 2025.

Michael L. Levitz, EVP, CFO, and Treasurer of Anika Therapeutics, reports the acquisition of restricted stock units and stock options.

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, acquired stock options and restricted stock units (RSUs) on March 15, 2024.

Anne Nunes, SVP, Chief Operations Officer of Anika Therapeutics, reports the acquisition of restricted stock units and stock options.

Cheryl Blanchard, CEO of Anika Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) as part of her compensation.

Cheryl Blanchard, CEO of Anika Therapeutics, reports the vesting of restricted stock units and related stock transactions.

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Anika Therapeutics' SVP, Chief Operations Officer Anne Nunes, reports acquisition and disposal of common stock related to the vesting of Restricted Stock Units (RSUs) to satisfy tax obligations.

Michael L. Levitz, EVP, CFO, and Treasurer of Anika Therapeutics, reports the vesting of restricted stock units and subsequent stock transactions to cover tax obligations.